Is Johnson & Johnson Stock Outperforming the Nasdaq?

Johnson & Johnson location sign-by JHVEPhoto via iStock

Sohini Mondal

Tue, February 24, 2026 at 10:01 PM GMT+9 2 min read

In this article:

JNJ

+0.84%

^IXIC

+0.76%

With a market cap of $592.4 billion, New Brunswick, New Jersey-based Johnson & Johnson (JNJ)is a global healthcare company engaged in the research, development, manufacturing, and sale of a broad range of medical products worldwide. The company serves patients and healthcare professionals through hospitals, wholesalers, retailers, and clinics around the world.

Companies valued at $200 billion or more are generally considered “mega-cap” stocks and Johnson & Johnson fits this criterion perfectly. It operates through two main segments: Innovative Medicine, which focuses on therapies across areas such as oncology, immunology, neuroscience, and cardiovascular disease, and MedTech, which delivers solutions for surgery, orthopedics, cardiovascular care, and vision health.

More News from Barchart

Why Citi Analysts Think You Should Buy Microsoft Stock Now

Netflix Investors Breathe Sigh of Relief: $83 Billion WBD Deal In DOJ Crosshairs

Stanley Druckenmiller Just Exited Sandisk Stock. Should You Buy SNDK After Its Blowout Earnings?

Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.

JNJ stock has seen a marginal decline from its 52-week high of $246.96. Over the past three months, its shares have increased 20.6%, outperforming the Nasdaq Composite’s ($NASX) 1.6% rise during the same period.

www.barchart.com

Longer term, JNJ stock is up 18.8% on a YTD basis, outpacing NASX’s 2.6% decline. Moreover, shares of the world’s biggest maker of health care products have surged 51.5% over the past 52 weeks, compared to NASX’s 15.9% return over the same time frame.

JNJ stock has exhibited a bullish trend, consistently trading above its 50-day and 200-day moving averages since July 2025.

www.barchart.com

Despite beating estimates with Q4 2025 adjusted EPS of $2.46 and revenue of $24.56 billion, Johnson & Johnson shares slipped marginally on Jan. 21. Key concerns included the expected “hundreds of millions of dollars” impact from a U.S. drug pricing deal and about $500 million in tariffs on its medical devices business, even as the company forecast strong 2026 sales of $99.5 billion - $100.5 billion.

In comparison, JNJ stock has outperformed its rival, Eli Lilly and Company (LLY). LLY stock has dipped 1.5% YTD and gained 21.2% over the past 52 weeks.

Despite the stock’s strong performance relative to the sector over the past year, analysts are cautiously optimistic about its prospects. JNJ stock has a consensus rating of “Moderate Buy” from the 26 analysts covering the stock, and as of writing, the stock is trading above the mean price target of $233.28.

_ On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com _

條款 及 私隱政策

Privacy Dashboard

More Info